Shots:
The companies expanded their alliance to add 4 long-acting, Regeneron-invented antibodies targeting IL-13 (REGN20423), IL-4×IL-13 bispecific, IL-4 & IL-4Rα. REGN20423 is in P-I for atopic dermatitis, while the other 3 are expected to enter clinical studies in 2027
As per the expanded agreement, Regeneron & Sanofi will co-develop & co-commercialize the assets, with Regeneron…
